Ignite Creation Date:
2024-05-11 @ 8:31 AM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06408038
Status:
RECRUITING
Last Update Posted:
2024-07-10
First Post:
2024-05-06
Brief Title:
Are CKCD45 Double-Positive Circulating Cells of Tumor-origin Characterization in METAstatic Breast Cancer
Sponsor:
Institut Claudius Regaud
Organization:
Institut Claudius Regaud
Study Overview
Official Title:
Are CKCD45 Double-Positive Circulating Cells of Tumor-origin Characterization in METAstatic Breast Cancer
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
DP METABREAST
Brief Summary:
A prospective single-centre proof-of-concept pilot study in patients with metastatic breast cancers MBC whatever the immunohistochemical subtype treated at the IUCT-O Eligible patients will be selected and informed of this study during a medical consultation for cancer that has metastasised has relapsed or is progressing metastatically by medical oncologists at the Oncopole Claudius Regaud OCR Then with the patients agreement and before the start of anti-tumour treatment a blood sample will be taken to detect DP-circulating cells A breast cancer tumour sample non-bone metastasis or failing that primary tumour must be available FFPE archived tumour block
Each patient will participate in the study for one day
60 patients will be included in this interventional study
Each patient will participate in the study for one day
60 patients will be included in this interventional study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None